Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Satellos Bioscience Inc. (V:MSCL)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for MSCL within the last 6 months
See all filings within the past 6 months

Company News

Jun 24, 2022 08:35 ET
Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing
Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23rd Life Sciences Investor Forum are now available for on-demand viewing. REGISTER NOW OR LOGIN AT:...
Read full article
Jun 22, 2022 07:00 ET
Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Officially Recognized as a Fellow of the Royal Society
Toronto, Ontario--(Newsfile Corp. - June 22, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has been admitted as a Fellow of the Royal Society, the UK's national science academy and a Fellowship of the world's most revered scientists. With admission to the Royal Society, founded in 1660 by grant of royal charter by King Charles II, Dr. Rudnicki joins an exclusive collective of Fellows including some of the most influential and respected scientists of all time, including Sir Isaac Newton and Charles Darwin.
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 15, 202251,41843,160
May 31, 20228,2581,872
May 15, 20226,386-26,583
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Satellos Bioscience Inc. is a Canada-based biotechnology and drug development company. The Company is focused on developing medicines to treat degenerative muscle conditions. The Company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. It uses MyoReGenX discovery platform to map pathways which modulate muscle repair and regeneration, identify and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its iCo Portfolio consists of two technologies namely the Oral Amp B Delivery System and Bertilimumab (previously iCo-008). Bertilimumab is a human monoclonal antibody that neutralizes eotaxin-1, a ligand to the C-C chemokine receptor type three to treat a range of allergic and inflammatory conditions.

See business summary



Search (past week) for $MSCL.CA MSCL.V